Medicare to Negotiate Prices for 15 More Drugs, Including Ozempic
By India Edwards HealthDay Reporter
WEDNESDAY, Jan. 22, 2025 -- Medicare will soon negotiate prices for 15 more drugs as part of an effort to reduce costs for seniors and people with disabilities, federal health officials announced in a news release.
The negotiations, made possible by the Inflation Reduction Act, will cover widely used medications for conditions such as type 2 diabetes, cancer, and asthma.
The new prices are expected to take effect in 2027.
Between November 2023 and October 2024, these selected drugs accounted for about $41 billion in total covered prescription drug costs under Medicare Part D, or about 14%, according to the U.S. Department of Health and Human Services (HHS).
“Today’s announcement is pivotal -- the Inflation Reduction Act is lowering prices for people on Medicare. HHS will continue negotiating in the best interest of people with Medicare to have access to innovative, life-saving treatments at lower costs," Xavier Becerra, HHS secretary under the Biden administration, said in the release.
Drugs selected for this second round of negotiations include:
-
Trelegy Ellipta
-
Pomalyst
-
Ibrance
-
Ofev
-
Linzess
-
Calquence
-
Austedo; Austedo XR
-
Breo Ellipta
-
Tradjenta
-
Xifaxan
-
Janumet; Janumet XR
-
Otezla
The new talks follow last year’s negotiations for 10 high-cost drugs, which resulted in price cuts of 38% to 79%. Those discounts, effective in 2026, are projected to save Medicare $6 billion annually.
Officials plan to expand negotiations to include 15 more drugs in the next cycle and up to 20 more in following years.
“Improving prescription drug affordability for Medicare enrollees is the core of the Inflation Reduction Act, and the next cycle of negotiations will continue to strengthen Medicare for generations to come," Chiquita Brooks-LaSure, administrator of the Centers for Medicare & Medicaid Services, said in the news release.
Sources
- Centers for Medicare & Medicaid Services, news release, Jan. 17, 2025
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted January 2025
Read this next
GI Cancers On The Rise Among Younger Adults
MONDAY, July 21, 2025 — GI cancers among people 50 and younger are rising at an alarming rate, increasing in the U.S. faster than any other type of early onset cancer...
Increasing Walk Cadence Counters Frailty Among Seniors, Study Says
MONDAY, July 21, 2025 — Putting a little more pep in the step could help elderly folks improve their health and remain independent, a new study says. Older adults who...
Slower Arm Movement Increases Fall Risk Among Seniors
MONDAY, July 21, 2025 — Seniors might be more prone to bone-breaking falls because they are unable to react quickly enough to regain their balance, a new study says. When a...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.